Compare BAC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAC | AZN |
|---|---|---|
| Founded | 1784 | 1992 |
| Country | United States | United Kingdom |
| Employees | 213000 | 96100 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.6B | 316.4B |
| IPO Year | N/A | N/A |
| Metric | BAC | AZN |
|---|---|---|
| Price | $56.15 | $177.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $60.34 | N/A |
| AVG Volume (30 Days) | ★ 34.9M | 1.9M |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.12% | 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.11 | $10.34 |
| Revenue Next Year | $5.80 | $6.43 |
| P/E Ratio | ★ $14.01 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.06 | $68.62 |
| 52 Week High | $57.55 | $212.71 |
| Indicator | BAC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 72.09 | 41.56 |
| Support Level | $51.20 | $174.60 |
| Resistance Level | $57.21 | $191.50 |
| Average True Range (ATR) | 1.14 | 3.17 |
| MACD | 0.43 | -0.18 |
| Stochastic Oscillator | 87.72 | 20.89 |
Bank of America is a formidable financial titan with a $3.5 trillion balance sheet and a cornerstone of the American economy, holding the second-largest deposit market share in the United States. While the firm has maintained its stronghold among middle-market and retail clientele domestically, Bank of America has continued to hold its own on the global stage, as evidenced by its fourth-largest global trading operation and an investment banking division that regularly finishes in the top four in global league tables. The firm is organized across four segments: consumer banking, global wealth and investment management, global banking, and global markets.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.